{"status": "Ok", "redirect_url": "https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2026/Teva-Submits-NDA-for-Ecopipam-a-First-in-Class-Investigational-Therapy-for-Pediatric-Tourette-Syndrome/default.aspx", "message": "News view counter 807954 successfully enlarged"}